A Peptide Binding to the β-Site of APP Improves Spatial Memory and Attenuates Aβ Burden in Alzheimer's Disease Transgenic Mice

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Yang, Shi gao ^a   Wang, Shao wei ^a,b   Zhao, Min ^a   Zhang, Ran ^a   Zhou, Wei wei ^a   Li, Ya nan ^a,c   Su, Ya jing ^a,c   Zhang, He ^a   Yu, Xiao lin ^b   Liu, Rui tian ^a,b  

^a Tsinghua University   (China)

^b INSTITUTE OF PROCESS ENGINEERING   (China)

^c NINGXIA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE 1;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN LEVEL; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; SEQUENCE ANALYSIS; SPATIAL MEMORY; TRANSGENIC MOUSE; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MAZE LEARNING; MEMORY; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ANALYSIS, DNA; SPATIAL BEHAVIOR; TETRAZOLIUM SALTS; THIAZOLES;

MUS MUSCULUS;

EID: 84868333825     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048540     Document Type: Article

References (77)

1. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, et al. (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156: 15-20.
2. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
3. Selkoe DJ, (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399: A23-31.
4. De Strooper B (2000) Alzheimer's disease. Closing in on gamma-secretase. Nature 405: 627, 629.
5. Quiroz-Baez R, Rojas E, Arias C, (2009) Oxidative stress promotes JNK-dependent amyloidogenic processing of normally expressed human APP by differential modification of alpha-, beta- and gamma-secretase expression. Neurochem Int 55: 662-670.
6. Liu R, McAllister C, Lyubchenko Y, Sierks MR, (2004) Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. Biochemistry 43: 9999-10007.
7. Dong Y, Xu Z, Zhang Y, McAuliffe S, Wang H, et al. (2011) RNA interference-mediated silencing of BACE and APP attenuates the isoflurane-induced caspase activation. Med Gas Res 1: 5.
8. Haass C, (2004) Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J 23: 483-488.
9. Ebke A, Luebbers T, Fukumori A, Shirotani K, Haass C, et al. (2011) Novel gamma-secretase enzyme modulators directly target presenilin protein. J Biol Chem 286: 37181-37186.
10. Hawkins J, Harrison DC, Ahmed S, Davis RP, Chapman T, et al. (2011) Dynamics of Abeta42 reduction in plasma, CSF and brain of rats treated with the gamma-secretase modulator, GSM-10 h. Neurodegener Dis 8: 455-464.
11. Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, et al. (2010) Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67: 769-780.
12. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC, (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59: 1381-1389.
13. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G, (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51: 783-786.
14. Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ, (2002) alpha- and beta-secretase: profound changes in Alzheimer's disease. Biochem Biophys Res Commun 299: 373-376.
15. Yang LB, Lindholm K, Yan R, Citron M, Xia W, et al. (2003) Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9: 3-4.
16. Harada H, Tamaoka A, Ishii K, Shoji S, Kametaka S, et al. (2006) Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. Neurosci Res 54: 24-29.
17. Li R, Lindholm K, Yang LB, Yue X, Citron M, et al. (2004) Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A 101: 3632-3637.
18. Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, et al. (2007) Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci 27: 3639-3649.
19. Jo DG, Arumugam TV, Woo HN, Park JS, Tang SC, et al. (2010) Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer's disease. Neurobiol Aging 31: 917-925.
20. Velliquette RA, O'Connor T, Vassar R, (2005) Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 25: 10874-10883.
21. Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, et al. (2011) Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J 25: 775-784.
22. Probst GD, Bowers S, Sealy JM, Stupi B, Dressen D, et al. (2010) Design and synthesis of hydroxyethylamine (HEA) BACE1 inhibitors: structure-activity relationship of the aryl region. Bioorg Med Chem Lett 20: 6034-6039.
23. Dominguez JL, Christopeit T, Villaverde MC, Gossas T, Otero JM, et al. (2010) Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE1. Biochemistry 49: 7255-7263.
24. Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, et al. (2003) The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem 278: 48713-48719.
25. Kitazume S, Tachida Y, Oka R, Shirotani K, Saido TC, et al. (2001) Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc Natl Acad Sci U S A 98: 13554-13559.
26. Kitazume S, Tachida Y, Oka R, Kotani N, Ogawa K, et al. (2003) Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta-secretase (BACE1). J Biol Chem 278: 14865-14871.
27. Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, et al. (2005) beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. J Biol Chem 280: 23009-23017.
28. Li Q, Sudhof TC, (2004) Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. J Biol Chem 279: 10542-10550.
29. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, et al. (2006) Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314: 664-666.
30. Hu X, Hicks CW, He W, Wong P, Macklin WB, et al, (2006) Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9: 1520-1525.
31. Hunt CE, Turner AJ, (2009) Cell biology, regulation and inhibition of beta-secretase (BACE1). FEBS J 276: 1845-1859.
32. Laird FM, Cai H, Savonenko AV, Farah MH, He K, et al. (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25: 11693-11709.
33. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, et al. (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41: 27-33.
34. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, et al. (2007) Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem 282: 26326-26334.
35. Ma H, Lesne S, Kotilinek L, Steidl-Nichols JV, Sherman M, et al. (2007) Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc Natl Acad Sci U S A 104: 8167-8172.
36. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, et al. (2005) Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 280: 30797-30806.
37. Rakover I, Arbel M, Solomon B, (2007) Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels. Neurodegener Dis 4: 392-402.
38. Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, et al. (2007) Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci U S A 104: 11062-11067.
39. Boddapati S, Levites Y, Sierks MR, (2011) Inhibiting beta-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP. J Mol Biol 405: 436-447.
40. Arbel-Ornath M, Becker M, Rabinovich-Toidman P, Gartner M, Solomon B, (2010) Immunomodulation of AbetaPP processing alleviates amyloid-beta-related pathology in Alzheimer's disease transgenic mice. J Alzheimers Dis 22: 469-482.
41. Boddapati S, Levites Y, Suryadi V, Kasturirangan S, Sierks MR, (2012) Bispecific Tandem Single Chain Antibody Simultaneously Inhibits beta-Secretase and Promotes alpha-Secretase Processing of AbetaPP. J Alzheimers Dis 28: 961-969.
42. Xue D, Zhao M, Wang YJ, Wang L, Yang Y, et al. (2012) A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting Aβ42-induced cytotoxicity and increasing microglial phagocytosis. Neurobiol Dis 46: 701-709.
43. Koo ED, Squazzo SL, (1994) Evidence that production and release of amyloid β-Protein involves the endocytic pathway. J Biol Chem 269: 17386-17389.
44. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, et al. (2005) Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci 25: 2455-2462.
45. Fukuchi K, Accavitti-Loper MA, Kim HD, Tahara K, Cao Y, et al. (2006) Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model. Biochem Biophys Res Commun 344: 79-86.
46. Janusz M, Woszczyna M, Lisowski M, Kubis A, Macala J, et al. (2009) Ovine colostrum nanopeptide affects amyloid beta aggregation. FEBS Lett 583: 190-196.
47. Vorhees CV, Williams MT, (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1: 848-858.
48. Feng Y, Yang SG, Du XT, Zhang X, Sun XX, et al. (2009) Ellagic acid promotes Abeta42 fibrillization and inhibits Abeta42-induced neurotoxicity. Biochem Biophys Res Commun 390: 1250-1254.
49. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.
50. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, et al. (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27: 796-807.
51. Liu R, Yuan B, Emadi S, Zameer A, Schulz P, et al. (2004) Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 43: 6959-6967.
52. Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, et al. (2006) Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 60: 668-676.
53. Yin F, Liu J, Ji X, Wang Y, Zidichouski J, et al. (2011) Silibinin: A novel inhibitor of Abeta aggregation. Neurochem Int 58: 399-403.
54. Yang SG, Zhang X, Sun XS, Ling TJ, Feng Y, et al. (2010) Diverse ecdysterones show different effects on amyloid-beta42 aggregation but all uniformly inhibit amyloid-beta42-induced cytotoxicity. J Alzheimers Dis 22: 107-117.
55. Cole SL, Vassar R, (2007a) The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener 2: 22.
56. Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, et al. (2007) BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis 26: 134-145.
57. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, et al. (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8: 1343-1349.
58. Vassar R, Kandalepas PC, (2011) The beta-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease. Alzheimers Res Ther 3: 20.
59. Mancini F, De Simone A, Andrisano V, (2011) Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors. Anal Bioanal Chem 400: 1979-1996.
60. Ortega A, Rincon A, Jimenez-Aliaga KL, Bermejo-Bescos P, Martin-Aragon S, et al. (2011) Synthesis and evaluation of arylquinones as BACE1 inhibitors, beta-amyloid peptide aggregation inhibitors, and destabilizers of preformed beta-amyloid fibrils. Bioorg Med Chem Lett 21: 2183-2187.
61. Zhou L, Chavez-Gutierrez L, Bockstael K, Sannerud R, Annaert W, et al. (2011) Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1. J Biol Chem 286: 8677-8687.
62. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, et al. (2011) A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med 3: 84ra43.
63. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, et al. (2010) A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci 30: 11157-11166.
64. Zhu Z, Li C, Wang X, Yang Z, Chen J, et al. (2010) 2,2′,4′-trihydroxychalcone from Glycyrrhiza glabra as a new specific BACE1 inhibitor efficiently ameliorates memory impairment in mice. J Neurochem 114: 374-385.
65. Wang H, Song L, Laird F, Wong PC, Lee HK, (2008) BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J Neurosci 28: 8677-8681.
66. Cole SL, Vassar R, (2008) BACE1 structure and function in health and Alzheimer's disease. Curr Alzheimer Res 5: 100-120.
67. Devi L, Ohno M, (2010) Phospho-eIF2alpha level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice. PLoS One 5: e12974.
68. Cole SL, Vassar R, (2007b) The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease. Curr Genomics 8: 509-530.
69. Bravo R, Arimon M, Valle-Delgado JJ, Garcia R, Durany N, et al. (2008) Sulfated polysaccharides promote the assembly of amyloid beta(1-42) peptide into stable fibrils of reduced cytotoxicity. J Biol Chem 283: 32471-32483.
70. Legleiter J, Czilli DL, Gitter B, DeMattos RB, Holtzman DM, (2004) Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J Mol Biol 335: 997-1006.
71. Solomon B, (2002) Anti-aggregating antibodies, a new approach towards treatment of conformational diseases. Curr Med Chem 9: 1737-1749.
72. Fabian H, Szendrei GI, Mantsch HH, Greenberg BD, Otvos L Jr, (1994) Synthetic post-translationally modified human A beta peptide exhibits a markedly increased tendency to form beta-pleated sheets in vitro. Eur J Biochem 221: 959-964.
73. Qahwash I, Weiland KL, Lu Y, Sarver RW, Kletzien RF, (2003) Identification of a mutant amyloid peptide that predominantly forms neurotoxic protofibrillar aggregates. J Biol Chem 278: 23187-23195.
74. Pike CJ, Overman MJ, Cotman CW, (1995) Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 270: 23895-23898.
75. Orner BP, Liu L, Murphy RM, Kiessling LL, (2006) Phage display affords peptides that modulate beta-amyloid aggregation. J Am Chem Soc 128: 11882-11889.
76. Devi L, Ohno M, (2012) 7,8-Dihydroxyflavone, a Small-Molecule TrkB Agonist, Reverses Memory Deficits and BACE1 Elevation in a Mouse Model of Alzheimer's Disease. Neuropsychopharmacology 37: 434-444.
77. McAllister C, Long J, Bowers A, Walker A, Cao P, et al. (2010) Genetic targeting aromatase in male amyloid precursor protein transgenic mice down-regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairment. J Neurosci 30: 7326-7334.